ADVERTISEMENT

Women's Health

Biden Proposes Requiring Private Insurance To Pay For OTC Birth Control As Elections Approach

Biden Proposes Requiring Private Insurance To Pay For OTC Birth Control As Elections Approach

Biden’s order for proposed rules could boost support for Democrat Kamla Harris from undecided voters concerned about reproductive rights or for Republican Donald Trump from those who agree with his conservative stance on access to birth control, which he argues should be up to states to regulate. Proposed rules also could stir consumers not planning to vote to go to the polls.

ML-Based Neuromodulation, Tele-Robotic Medical Imaging Among Octane Medical Innovation Forum Highlights

ML-Based Neuromodulation, Tele-Robotic Medical Imaging Among Octane Medical Innovation Forum Highlights

Start-ups pitched a diverse deck of innovative technologies to three judges and an audience of potential investors, strategics and physicians at the Octane Medical Innovation Forum in Irvine, CA. Highlights include neuromodulation company Sinaptica Therapeutics, which won the competition for both “People’s Choice” and “Judge’s Choice.”

FDA Publishes Updated Roadmap For Advancing Women’s Health

FDA Publishes Updated Roadmap For Advancing Women’s Health

The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.

Marabio Systems Raised $19M In Series A For Blood Test To Detect Autism

Marabio Systems Raised $19M In Series A For Blood Test To Detect Autism

Marabio Systems says the new funding will help accelerate efforts to bring a blood test to market in 2025 that will accurately determine if a mother is a carrier of antibodies that cause MARA, a subtype of autism that believe to cause more severe behavior.

FDA Publishes Updated ‘Roadmap’ For Advancing Women’s Health

FDA Publishes Updated ‘Roadmap’ For Advancing Women’s Health

The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.

Taisho’s UPSA Acquires Sérélys To Enter Women’s Health Market in France And Abroad

Taisho’s UPSA Acquires Sérélys To Enter Women’s Health Market in France And Abroad

Monaco-based Sérélys markets pollen-based supplements for a range of women's health issues, including premenstrual syndrome, postpartum discomfort and menopause.

UK’s Maxwellia Looking For £2m Investment To Fuel ‘Next Phase Of Rapid Growth’

UK’s Maxwellia Looking For £2m Investment To Fuel ‘Next Phase Of Rapid Growth’

Maxwellia is inviting 100 investors to contribute to the “development of new healthcare solutions that will benefit millions, while also playing a role in shaping the future of self-care.”

Perelel Adds Women’s Health Education Platform, Plum Debuts With Vaginal Area Dryness Serum

Perelel Adds Women’s Health Education Platform, Plum Debuts With Vaginal Area Dryness Serum

Perelel acquiring Loom online platform providing reproductive health, sexual wellness and parenting education. First direct-to-consumer product for Curive Healthcare’s Plum brand formulated for vaginal area dryness.

News We’re Watching: Neuralink’s Blindsight Gets FDA Breakthrough Device Tag; FDA Pump Recalls, Guidances; Discure, DeepLook Bolster Coffers

News We’re Watching: Neuralink’s Blindsight Gets FDA Breakthrough Device Tag; FDA Pump Recalls, Guidances; Discure, DeepLook Bolster Coffers

This week, Neuralink announced it received US FDA breakthrough device designation for a device to restore sight; medtechs Discure and DeepLook secured new funding; FDA pump recalls from B. Braun Medical and Fresenius Kabi; Axonics prevails in patent infringement lawsuit with Medtronic; Merit Medical buys Cook Medical for $210m.

ESMO 24: Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer

ESMO 24: Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer

The Copenhagen-headquartered group is taking its antibody-drug conjugate rinatabart sesutecan into Phase III and chief medical officer Tahi Ahmadi tells Scrip that it has the potential to treat far more women than the only currently marketed FRα-targeting ADC, AbbVie's Elahere.